{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T12:48:44Z","timestamp":1793710124687,"version":"4.6.1"},"reference-count":209,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,11]],"date-time":"2022-04-11T00:00:00Z","timestamp":1649635200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Obesity Pillars"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.obpill.2022.100018","type":"journal-article","created":{"date-parts":[[2022,4,15]],"date-time":"2022-04-15T19:25:26Z","timestamp":1650050726000},"page":"100018","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"special_numbering":"C","title":["Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022"],"prefix":"10.1016","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9912-1408","authenticated-orcid":false,"given":"Harold E.","family":"Bays","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Fitch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karli","family":"Burridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Tondt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.obpill.2022.100018_bib1","author":"Bays"},{"key":"10.1016\/j.obpill.2022.100018_bib2","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s13679-017-0262-y","article-title":"Weight loss and improvement in comorbidity: differences at 5%, 10%, 15%, and over","volume":"6","author":"Ryan","year":"2017","journal-title":"Curr Obes Rep"},{"key":"10.1016\/j.obpill.2022.100018_bib3","article-title":"Obesity history, physical exam, laboratory, body composition, and energy expenditure: an Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022","volume":"1","author":"Burridge","year":"2022","journal-title":"Obes Pillars"},{"key":"10.1016\/j.obpill.2022.100018_bib4","article-title":"Obesity definition, diagnosis, bias, standard operating procedures (SOPs), and telehealth: an Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022","volume":"1","author":"Fitch","year":"2022","journal-title":"Obes Pillars"},{"key":"10.1016\/j.obpill.2022.100018_bib5","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1002\/oby.20394","article-title":"Why do we need drugs to treat the patient with obesity?","volume":"21","author":"Bray","year":"2013","journal-title":"Obesity"},{"key":"10.1016\/j.obpill.2022.100018_bib6","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.soard.2016.10.018","article-title":"The utility of weight loss medications after bariatric surgery for weight regain or inadequate weight loss: a multi-center study","volume":"13","author":"Stanford","year":"2017","journal-title":"Surg Obes Relat Dis"},{"key":"10.1016\/j.obpill.2022.100018_bib7","author":"Food and Drug Administration"},{"key":"10.1016\/j.obpill.2022.100018_bib8","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jacl.2015.08.002","article-title":"National lipid association annual summary of clinical lipidology 2016","volume":"10","author":"Bays","year":"2016","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.obpill.2022.100018_bib9","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1056\/NEJM200103293441307","article-title":"Interactions among drugs for HIV and opportunistic infections","volume":"344","author":"Piscitelli","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.obpill.2022.100018_bib10","doi-asserted-by":"crossref","first-page":"F273","DOI":"10.1152\/ajprenal.00547.2014","article-title":"Obesity and renovascular disease","volume":"309","author":"Zhang","year":"2015","journal-title":"Am J Physiol Ren Physiol"},{"key":"10.1016\/j.obpill.2022.100018_bib11","doi-asserted-by":"crossref","DOI":"10.3390\/molecules23071719","article-title":"Salts of therapeutic agents: chemical, physicochemical, and biological considerations","volume":"23","author":"Gupta","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.obpill.2022.100018_bib12","first-page":"903","volume":"vol. 47","author":"Bays","year":"2011"},{"key":"10.1016\/j.obpill.2022.100018_bib13","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1586\/erc.10.125","article-title":"Phentermine, topiramate and their combination for the treatment of adiposopathy ('sick fat') and metabolic disease","volume":"8","author":"Bays","year":"2010","journal-title":"Expet Rev Cardiovasc Ther"},{"key":"10.1016\/j.obpill.2022.100018_bib19","first-page":"S43","article-title":"Individualizing treatment with statin therapy","volume":"67","author":"Bays","year":"2018","journal-title":"J\u00a0Fam Pract"},{"key":"10.1016\/j.obpill.2022.100018_bib20","doi-asserted-by":"crossref","first-page":"223","DOI":"10.4103\/1008-682X.122365","article-title":"Lowered testosterone in male obesity: mechanisms, morbidity and management","volume":"16","author":"Fui","year":"2014","journal-title":"Asian J Androl"},{"key":"10.1016\/j.obpill.2022.100018_bib21","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1159\/000496564","article-title":"Hypothalamic obesity: prologue and promise","volume":"91","author":"Abuzzahab","year":"2019","journal-title":"Horm Res Paediatr"},{"key":"10.1016\/j.obpill.2022.100018_bib22","article-title":"Management of hypopituitarism","volume":"8","author":"Alexandraki","year":"2019","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.obpill.2022.100018_bib23","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2165\/00003088-200039030-00004","article-title":"Effects of obesity on pharmacokinetics implications for drug therapy","volume":"39","author":"Cheymol","year":"2000","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.obpill.2022.100018_bib24","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.amjcard.2013.08.041","article-title":"Evaluation of lipids, drug concentration, and safety parameters following cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib in patients with or at high risk for coronary heart disease","volume":"113","author":"Gotto","year":"2014","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.obpill.2022.100018_bib25","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1038\/ijo.2011.242","article-title":"Interpreting different measures of glomerular filtration rate in obesity and weight loss: pitfalls for the clinician","volume":"36","author":"Jesudason","year":"2012","journal-title":"Int J Obes"},{"key":"10.1016\/j.obpill.2022.100018_bib26","doi-asserted-by":"crossref","first-page":"393","DOI":"10.23736\/S0393-2249.18.03113-2","article-title":"Obesity and kidney stone disease: a systematic review","volume":"70","author":"Carbone","year":"2018","journal-title":"Minerva Urol Nefrol"},{"key":"10.1016\/j.obpill.2022.100018_bib27","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s40265-017-0853-7","article-title":"Drug-induced kidney stones and crystalline nephropathy: pathophysiology, prevention and treatment","volume":"78","author":"Daudon","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.obpill.2022.100018_bib28","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1053\/j.ajkd.2006.07.003","article-title":"Biochemical and stone-risk profiles with topiramate treatment","volume":"48","author":"Welch","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.obpill.2022.100018_bib29","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.3109\/0886022X.2012.723777","article-title":"Renal stone disease and obesity: what is important for urologists and nephrologists?","volume":"34","author":"Ahmed","year":"2012","journal-title":"Ren Fail"},{"key":"10.1016\/j.obpill.2022.100018_bib30","series-title":"Mayo Clinic proceedings","first-page":"774","article-title":"Clinical interpretation of urine drug tests: what clinicians need to know about urine drug screens","volume":"92","author":"Moeller","year":"2017"},{"key":"10.1016\/j.obpill.2022.100018_bib31","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1586\/erc.10.22","article-title":"Lorcaserin: drug profile and illustrative model of the regulatory challenges of weight-loss drug development","volume":"9","author":"Bays","year":"2011","journal-title":"Expet Rev Cardiovasc Ther"},{"key":"10.1016\/j.obpill.2022.100018_bib32","article-title":"Obesity history, physical exam, laboratory, body composition, and energy expenditure: an Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022","volume":"1","author":"Burridge","year":"2022","journal-title":"Obes Pillars"},{"key":"10.1016\/j.obpill.2022.100018_bib33","article-title":"Obesity medicine association (OMA): advocacy update","volume":"1","author":"Francavilla","year":"2022","journal-title":"Obes Pillars"},{"key":"10.1016\/j.obpill.2022.100018_bib34","author":"Food and Drug Administration"},{"key":"10.1016\/j.obpill.2022.100018_bib35","author":"American College of Obstetricians and Gynecologists"},{"key":"10.1016\/j.obpill.2022.100018_bib36","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/01.AOG.0000425667.10377.60","article-title":"ACOG Committee opinion no. 549: obesity in pregnancy","volume":"121","author":"American College of Obstetricians Gynecologists","year":"2013","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.obpill.2022.100018_bib37","doi-asserted-by":"crossref","first-page":"632","DOI":"10.2337\/dc16-2427","article-title":"Coadministration of canagliflozin and phentermine for weight management in overweight and obese individuals without diabetes: a randomized clinical trial","volume":"40","author":"Hollander","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1016\/j.obpill.2022.100018_bib38","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1002\/oby.20584","article-title":"Evaluation of phentermine and topiramate versus phentermine\/topiramate extended-release in obese adults","volume":"21","author":"Aronne","year":"2013","journal-title":"Obesity"},{"key":"10.1016\/j.obpill.2022.100018_bib39","doi-asserted-by":"crossref","first-page":"614","DOI":"10.3349\/ymj.2006.47.5.614","article-title":"Effects on weight reduction and safety of short-term phentermine administration in Korean obese people","volume":"47","author":"Kim","year":"2006","journal-title":"Yonsei Med J"},{"key":"10.1016\/j.obpill.2022.100018_bib40","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1001\/archinte.161.15.1814","article-title":"Long-term pharmacotherapy of obesity 2000: a review of efficacy and safety","volume":"161","author":"Glazer","year":"2001","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.obpill.2022.100018_bib41","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1097\/SAP.0000000000001478","article-title":"Phentermine: a systematic review for plastic and reconstructive surgeons","volume":"81","author":"Lim","year":"2018","journal-title":"Ann Plast Surg"},{"key":"10.1016\/j.obpill.2022.100018_bib43","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.obpill.2022.100018_bib44","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1111\/dom.12502","article-title":"Current and emerging medications for overweight or obesity in people with comorbidities","volume":"17","author":"Fujioka","year":"2015","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.obpill.2022.100018_bib46","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S0140-6736(10)60888-4","article-title":"Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"376","author":"Greenway","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.obpill.2022.100018_bib47","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1002\/oby.20309","article-title":"A\u00a0randomized, phase 3 trial of naltrexone SR\/bupropion SR on weight and obesity-related risk factors (COR-II)","volume":"21","author":"Apovian","year":"2013","journal-title":"Obesity"},{"key":"10.1016\/j.obpill.2022.100018_bib48","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1159\/000430433","article-title":"An unexpected result of obesity treatment: orlistat-related acute pancreatitis","volume":"9","author":"Kose","year":"2015","journal-title":"Case Rep Gastroenterol"},{"key":"10.1016\/j.obpill.2022.100018_bib49","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/sj.ijo.0801889","article-title":"Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials","volume":"26","author":"Haddock","year":"2002","journal-title":"Int J Obes Relat Metabol Disord"},{"key":"10.1016\/j.obpill.2022.100018_bib50","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1038\/oby.2011.94","article-title":"Blood pressure and heart rate effects, weight loss and maintenance during long-term phentermine pharmacotherapy for obesity","volume":"19","author":"Hendricks","year":"2011","journal-title":"Obesity"},{"key":"10.1016\/j.obpill.2022.100018_bib51","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1002\/oby.22430","article-title":"Safety and effectiveness of longer-term phentermine use: clinical outcomes from an electronic health record cohort","volume":"27","author":"Lewis","year":"2019","journal-title":"Obesity"},{"key":"10.1016\/j.obpill.2022.100018_bib52","doi-asserted-by":"crossref","first-page":"223","DOI":"10.2147\/DMSO.S95299","article-title":"Off-label drugs for weight management","volume":"10","author":"Hendricks","year":"2017","journal-title":"Diabetes Metab Syndr Obes"},{"key":"10.1016\/j.obpill.2022.100018_bib53","article-title":"Medication-induced gastroparesis: a case report","volume":"9","author":"Kalas","year":"2021","journal-title":"J\u00a0Investig Med High Impact Case Rep"},{"key":"10.1016\/j.obpill.2022.100018_bib54","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1590\/S1807-59322009000700015","article-title":"Hypercalcitoninemia is not pathognomonic of medullary thyroid carcinoma","volume":"64","author":"Toledo","year":"2009","journal-title":"Clinics"},{"key":"10.1016\/j.obpill.2022.100018_bib55","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.2337\/dc18-2028","article-title":"Changes in serum calcitonin concentrations, incidence of medullary thyroid carcinoma, and impact of routine calcitonin concentration monitoring in the EXenatide study of cardiovascular event lowering (EXSCEL)","volume":"42","author":"Bethel","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.obpill.2022.100018_bib56","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1159\/000330447","article-title":"Incretin receptors in non-neoplastic and neoplastic thyroid C cells in rodents and humans: relevance for incretin-based diabetes therapy","volume":"94","author":"Waser","year":"2011","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.obpill.2022.100018_bib57","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1159\/000180860","article-title":"Calcitonin levels in chronic renal disease","volume":"19","author":"Silva","year":"1977","journal-title":"Nephron"},{"key":"10.1016\/j.obpill.2022.100018_bib58","author":"United States Drug Enforcement Administration"},{"key":"10.1016\/j.obpill.2022.100018_bib59","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/oby.2004.151","article-title":"Current and investigational antiobesity agents and obesity therapeutic treatment targets","volume":"12","author":"Bays","year":"2004","journal-title":"Obes Res"},{"key":"10.1016\/j.obpill.2022.100018_bib60","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s11936-007-0021-6","article-title":"Adiposopathy: treating pathogenic adipose tissue to reduce cardiovascular disease risk","volume":"9","author":"Bays","year":"2007","journal-title":"Curr Treat Options Cardiovasc Med"},{"key":"10.1016\/j.obpill.2022.100018_bib61","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/ijo.2009.124","article-title":"A\u00a0randomized double-blind placebo-controlled study of the long-term efficacy and safety of diethylpropion in the treatment of obese subjects","volume":"33","author":"Cercato","year":"2009","journal-title":"Int J Obes"},{"key":"10.1016\/j.obpill.2022.100018_bib62","first-page":"29","article-title":"Study of phendimetrazine bitartrate as an appetite suppressant in relation to dosage, weight loss and side effects","volume":"87","author":"Le Riche","year":"1962","journal-title":"Can Med Assoc J"},{"key":"10.1016\/j.obpill.2022.100018_bib63","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1586\/erc.09.123","article-title":"Lorcaserin and adiposopathy: 5-HT2c agonism as a treatment for 'sick fat' and metabolic disease","volume":"7","author":"Bays","year":"2009","journal-title":"Expet Rev Cardiovasc Ther"},{"key":"10.1016\/j.obpill.2022.100018_bib64","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/ijo.2013.74","article-title":"Addiction potential of phentermine prescribed during long-term treatment of obesity","volume":"38","author":"Hendricks","year":"2014","journal-title":"Int J Obes"},{"key":"10.1016\/j.obpill.2022.100018_bib65","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1210\/jc.2014-3415","article-title":"Pharmacological management of obesity: an endocrine Society clinical practice guideline","volume":"100","author":"Apovian","year":"2015","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"key":"10.1016\/j.obpill.2022.100018_bib66","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/dom.13538","article-title":"Worsening of diabetic retinopathy with rapid improvement in systemic glucose control: a review","volume":"21","author":"Bain","year":"2019","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.obpill.2022.100018_bib67","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1001\/archopht.116.7.874","article-title":"Early worsening of diabetic retinopathy in the diabetes control and complications trial","volume":"116","author":"Control","year":"1998","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.obpill.2022.100018_bib68","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.diabet.2017.10.014","article-title":"Early worsening of diabetic retinopathy after rapid improvement of blood glucose control in patients with diabetes","volume":"44","author":"Feldman-Billard","year":"2018","journal-title":"Diabetes Metabol"},{"key":"10.1016\/j.obpill.2022.100018_bib69","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/nrd.2016.75","article-title":"Targeting adipose tissue in the treatment of obesity-associated diabetes","volume":"15","author":"Kusminski","year":"2016","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.obpill.2022.100018_bib70","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1586\/14779072.4.6.871","article-title":"Adiposopathy: how do diet, exercise and weight loss drug therapies improve metabolic disease in overweight patients?","volume":"4","author":"Bays","year":"2006","journal-title":"Expet Rev Cardiovasc Ther"},{"key":"10.1016\/j.obpill.2022.100018_bib71","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1007\/s11892-019-1269-4","article-title":"Bariatric surgery in the treatment of type 2 diabetes","volume":"19","author":"Affinati","year":"2019","journal-title":"Curr Diabetes Rep"},{"key":"10.1016\/j.obpill.2022.100018_bib72","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1056\/NEJMoa1901118","article-title":"Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"381","author":"Husain","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.obpill.2022.100018_bib73","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","article-title":"Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial","volume":"397","author":"Davies","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.obpill.2022.100018_bib74","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1001\/jama.2021.1831","article-title":"Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial","volume":"325","author":"Wadden","year":"2021","journal-title":"JAMA : J Am Med Assoc"},{"key":"10.1016\/j.obpill.2022.100018_bib75","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1001\/jama.2021.3224","article-title":"Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial","volume":"325","author":"Rubino","year":"2021","journal-title":"JAMA: J Am Med Assoc"},{"key":"10.1016\/j.obpill.2022.100018_bib76","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1002\/oby.22794","article-title":"Semaglutide 2.4 mg for the treatment of obesity: key elements of the STEP trials 1 to 5","volume":"28","author":"Kushner","year":"2020","journal-title":"Obesity"},{"key":"10.1016\/j.obpill.2022.100018_bib77","author":"Nordisk"},{"issue":"3","key":"10.1016\/j.obpill.2022.100018_bib78","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S2213-8587(22)00008-0","article-title":"STEP 6 investigators. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial","volume":"10","author":"Kadowaki","year":"2022","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.obpill.2022.100018_bib79","unstructured":"Novo Nordisk. Research study of how well semaglutide works in people living with overweight or obesity (STEP 7). ClinicalTrials.gov Identifier: NCT04251156."},{"key":"10.1016\/j.obpill.2022.100018_bib80","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1001\/jama.2021.23619","article-title":"Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial","volume":"327","author":"Rubino","year":"2022","journal-title":"JAMA : J Am Med Assoc"},{"key":"10.1016\/j.obpill.2022.100018_bib81","author":"Nordisk"},{"key":"10.1016\/j.obpill.2022.100018_bib82","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.645566","article-title":"Cardiovascular safety and benefits of semaglutide in patients with type 2 diabetes: findings from SUSTAIN 6 and PIONEER 6","volume":"12","author":"Nauck","year":"2021","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.obpill.2022.100018_bib83","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ahj.2020.07.008","article-title":"Semaglutide effects on cardiovascular outcomes in people with overweight or obesity (SELECT) rationale and design","volume":"229","author":"Ryan","year":"2020","journal-title":"Am Heart J"},{"issue":"Suppl 3","key":"10.1016\/j.obpill.2022.100018_bib84","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/EP161365.GL","article-title":"American association of clinical endocrinologists and American college of endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity","volume":"22","author":"Garvey","year":"2016","journal-title":"Endocr Pract"},{"issue":"Suppl 1","key":"10.1016\/j.obpill.2022.100018_bib85","first-page":"S4","article-title":"Efficacy comparison of medications approved for chronic weight management","volume":"23","author":"Kumar","year":"2015","journal-title":"Obesity"},{"key":"10.1016\/j.obpill.2022.100018_bib86","first-page":"135","volume":"vol. 102","author":"Saunders","year":"2018"},{"key":"10.1016\/j.obpill.2022.100018_bib87","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1080\/03007995.2016.1251892","article-title":"Liraglutide 3.0 mg for weight management: weight-loss dependent and independent effects","volume":"33","author":"Bays","year":"2017","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.obpill.2022.100018_bib88","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1038\/ijo.2016.52","article-title":"Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial","volume":"40","author":"Blackman","year":"2016","journal-title":"Int J Obes"},{"key":"10.1016\/j.obpill.2022.100018_bib89","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1093\/ajcn\/nqaa328","article-title":"Liraglutide after diet-induced weight loss for pain and weight control in knee osteoarthritis: a randomized controlled trial","volume":"113","author":"Gudbergsen","year":"2021","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.obpill.2022.100018_bib90","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1467-789X.2006.00252.x","article-title":"The management of osteoarthritis in the obese patient: practical considerations and guidelines for therapy","volume":"7","author":"Bliddal","year":"2006","journal-title":"Obes Rev"},{"key":"10.1016\/j.obpill.2022.100018_bib91","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/obr.12173","article-title":"Osteoarthritis, obesity and weight loss: evidence, hypotheses and horizons - a scoping review","volume":"15","author":"Bliddal","year":"2014","journal-title":"Obes Rev"},{"key":"10.1016\/j.obpill.2022.100018_bib92","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41433-019-0603-z","article-title":"A\u00a0review of systemic medications that may modulate the risk of glaucoma","volume":"34","author":"Wu","year":"2020","journal-title":"Eye"},{"key":"10.1016\/j.obpill.2022.100018_bib93","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/j.1365-2125.2005.02470.x","article-title":"Topiramate in non-approved indications and acute myopia or angle closure glaucoma","volume":"60","author":"Cereza","year":"2005","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.obpill.2022.100018_bib94","doi-asserted-by":"crossref","first-page":"108","DOI":"10.4103\/0028-3886.15074","article-title":"Acute myopia induced by topiramate: report of a case and review of the literature","volume":"53","author":"Bhattacharyya","year":"2005","journal-title":"Neurol India"},{"key":"10.1016\/j.obpill.2022.100018_bib95","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/bcp.12720","article-title":"Treatment of drug-induced seizures","volume":"81","author":"Chen","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.obpill.2022.100018_bib96","first-page":"551","volume":"vol. 39","author":"Hedges","year":"2003"},{"issue":"Suppl 4","key":"10.1016\/j.obpill.2022.100018_bib97","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/j.1528-1167.2012.03622.x","article-title":"Causes of status epilepticus","volume":"53","author":"Trinka","year":"2012","journal-title":"Epilepsia"},{"key":"10.1016\/j.obpill.2022.100018_bib103","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"A\u00a0randomized, controlled trial of 3.0 mg of liraglutide in weight management","volume":"373","author":"Pi-Sunyer","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.obpill.2022.100018_bib104","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3945\/ajcn.111.024927","article-title":"Two-year sustained weight loss and metabolic benefits with controlled-release phentermine\/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study","volume":"95","author":"Garvey","year":"2012","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.obpill.2022.100018_bib105","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1001\/jama.281.3.235","article-title":"Weight control and risk factor reduction in obese subjects treated for 2 Years with OrlistatA randomized controlled trial","volume":"281","author":"Davidson","year":"1999","journal-title":"JAMA : J Am Med Assoc"},{"key":"10.1016\/j.obpill.2022.100018_bib106","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/oby.22347","article-title":"A\u00a0randomized, double-blind, placebo-controlled study of Gelesis100: a novel nonsystemic oral hydrogel for weight loss","volume":"27","author":"Greenway","year":"2019","journal-title":"Obesity"},{"key":"10.1016\/j.obpill.2022.100018_bib107","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/oby.22066","article-title":"The association between the dosage of SGLT2 inhibitor and weight reduction in type 2 diabetes patients: a meta-analysis","volume":"26","author":"Cai","year":"2018","journal-title":"Obesity"},{"key":"10.1016\/j.obpill.2022.100018_bib108","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1185\/03007990802710422","article-title":"From victim to ally: the kidney as an emerging target for the treatment of diabetes mellitus","volume":"25","author":"Bays","year":"2009","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.obpill.2022.100018_bib109","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1002\/oby.20663","article-title":"Canagliflozin: effects in overweight and obese subjects without diabetes mellitus","volume":"22","author":"Bays","year":"2014","journal-title":"Obesity"},{"key":"10.1016\/j.obpill.2022.100018_bib110","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1248\/yakushi.19-00120","article-title":"[Risk of euglycemic diabetic ketoacidosis due to low-carbohydrate diet while taking empagliflozin: a case report]","volume":"139","author":"Yamamoto","year":"2019","journal-title":"Yakugaku Zasshi"},{"key":"10.1016\/j.obpill.2022.100018_bib111","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1002\/oby.22764","article-title":"Licogliflozin, a novel SGLT1 and 2 inhibitor: body weight effects in a randomized trial in adults with overweight or obesity","volume":"28","author":"Bays","year":"2020","journal-title":"Obesity"},{"key":"10.1016\/j.obpill.2022.100018_bib112","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/S0140-6736(21)00536-5","article-title":"SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications","volume":"398","author":"Brown","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.obpill.2022.100018_bib113","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1177\/0269881117737401","article-title":"Combination therapy for obesity","volume":"31","author":"Wilding","year":"2017","journal-title":"J\u00a0Psychopharmacol"},{"key":"10.1016\/j.obpill.2022.100018_bib114","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/S2213-8587(19)30066-X","article-title":"Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial","volume":"7","author":"Zinman","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.obpill.2022.100018_bib115","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.2337\/dc19-1350","article-title":"Efficacy and safety over 2 Years of exenatide plus dapagliflozin in the DURATION-8 study: a multicenter, double-blind, phase 3, randomized controlled trial","volume":"43","author":"Jabbour","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.obpill.2022.100018_bib116","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s40608-017-0147-3","article-title":"Aggressive clinical approach to obesity improves metabolic and clinical outcomes and can prevent bariatric surgery: a single center experience","volume":"4","author":"Cadegiani","year":"2017","journal-title":"BMC Obes"},{"key":"10.1016\/j.obpill.2022.100018_bib117","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.metabol.2019.03.005","article-title":"Effects of liraglutide plus phentermine in adults with obesity following 1year of treatment by liraglutide alone: a randomized placebo-controlled pilot trial","volume":"96","author":"Tronieri","year":"2019","journal-title":"Metab, Clin Exp"},{"key":"10.1016\/j.obpill.2022.100018_bib118","doi-asserted-by":"crossref","first-page":"e482","DOI":"10.4158\/ACCR-2018-0125","article-title":"Combination of phentermine\/topiramate Er and liraglutide 3 Mg for intensive therapy of severe obesity & T2Dm: a case series and brief review","volume":"4","author":"Baloch","year":"2018","journal-title":"AACE Clin Case Rep"},{"key":"10.1016\/j.obpill.2022.100018_bib119","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1002\/oby.22786","article-title":"The mitigating effect of phentermine and topiramate on weight regain after roux-en-Y gastric bypass surgery","volume":"28","author":"Istfan","year":"2020","journal-title":"Obesity"},{"key":"10.1016\/j.obpill.2022.100018_bib120","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.soard.2017.10.002","article-title":"Efficacy of adjuvant weight loss medication after bariatric surgery","volume":"14","author":"Nor Hanipah","year":"2018","journal-title":"Surg Obes Relat Dis"},{"key":"10.1016\/j.obpill.2022.100018_bib121","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1002\/oby.23146","article-title":"Pharmacotherapies for post-bariatric weight regain: real-world comparative outcomes","volume":"29","author":"Gazda","year":"2021","journal-title":"Obesity"},{"key":"10.1016\/j.obpill.2022.100018_bib122","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1159\/000478872","article-title":"GLP-1\/GLP-1R signaling in regulation of adipocyte differentiation and lipogenesis","volume":"42","author":"Chen","year":"2017","journal-title":"Cell Physiol Biochem"},{"key":"10.1016\/j.obpill.2022.100018_bib123","volume":"vol. 59","author":"Bray","year":"2007"},{"key":"10.1016\/j.obpill.2022.100018_bib124","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJMoa1003114","article-title":"Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects","volume":"363","author":"James","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.obpill.2022.100018_bib125","doi-asserted-by":"crossref","DOI":"10.1111\/obr.13170","article-title":"Is lorcaserin really associated with increased risk of cancer? A systematic review and meta-analysis","volume":"22","author":"de Andrade Mesquita","year":"2021","journal-title":"Obes Rev"},{"key":"10.1016\/j.obpill.2022.100018_bib126","doi-asserted-by":"crossref","first-page":"630","DOI":"10.2174\/1389202919666180726125645","article-title":"A\u00a0network biology approach for assessing the role of pathologic adipose tissues in insulin resistance using meta-analysis of microarray datasets","volume":"19","author":"Saxena","year":"2018","journal-title":"Curr Genom"},{"key":"10.1016\/j.obpill.2022.100018_bib127","first-page":"801","article-title":"Pancreas is a preeminent source of ghrelin after sleeve gastrectomy in Wistar rats","volume":"35","author":"Camacho-Ram\u00edrez","year":"2020","journal-title":"Histol Histopathol"},{"key":"10.1016\/j.obpill.2022.100018_bib128","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jacl.2015.12.002","article-title":"Lipids and bariatric procedures part 1 of 2: scientific statement from the national Lipid Association, American Society for Metabolic and Bariatric Surgery, and Obesity Medicine Association: full report","volume":"10","author":"Bays","year":"2016","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.obpill.2022.100018_bib129","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.soard.2016.01.007","article-title":"Lipids and bariatric procedures Part 2 of 2: scientific statement from the American Society for Metabolic and Bariatric Surgery (ASMBS), the National Lipid Association (NLA), and Obesity Medicine Association (OMA)","volume":"12","author":"Bays","year":"2016","journal-title":"Surg Obes Relat Dis"},{"key":"10.1016\/j.obpill.2022.100018_bib130","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s13679-017-0276-5","article-title":"Potential hormone mechanisms of bariatric surgery","volume":"6","author":"Dimitriadis","year":"2017","journal-title":"Curr Obes Rep"},{"key":"10.1016\/j.obpill.2022.100018_bib131","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s11892-013-0364-1","article-title":"Clues from bariatric surgery: reversing insulin resistance to heal the heart","volume":"13","author":"Khalaf","year":"2013","journal-title":"Curr Diabetes Rep"},{"key":"10.1016\/j.obpill.2022.100018_bib132","doi-asserted-by":"crossref","first-page":"893","DOI":"10.2337\/dc16-0145","article-title":"Mechanisms of diabetes improvement following bariatric\/metabolic surgery","volume":"39","author":"Batterham","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.obpill.2022.100018_bib133","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.peptides.2015.08.013","article-title":"The effect of bariatric surgery on gastrointestinal and pancreatic peptide hormones","volume":"77","author":"Meek","year":"2016","journal-title":"Peptides"},{"key":"10.1016\/j.obpill.2022.100018_bib134","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1210\/jc.2013-2538","article-title":"Roux-en-Y gastric bypass and sleeve gastrectomy: mechanisms of diabetes remission and role of gut hormones","volume":"98","author":"Nannipieri","year":"2013","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"key":"10.1016\/j.obpill.2022.100018_bib135","doi-asserted-by":"crossref","first-page":"121","DOI":"10.4103\/njs.NJS_24_17","article-title":"Role of hunger hormone \"Ghrelin\u201d in long-term weight loss following laparoscopic sleeve gastrectomy","volume":"24","author":"Sethi","year":"2018","journal-title":"Niger J Surg"},{"key":"10.1016\/j.obpill.2022.100018_bib136","doi-asserted-by":"crossref","first-page":"544","DOI":"10.4103\/ijmr.IJMR_984_18","article-title":"Plasma ghrelin levels after laparoscopic sleeve gastrectomy in obese individuals","volume":"149","author":"Sharma","year":"2019","journal-title":"Indian J Med Res"},{"key":"10.1016\/j.obpill.2022.100018_bib137","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1007\/s11695-018-03686-3","article-title":"Systematic review and meta-analysis of the change in Ghrelin levels after roux-en-Y gastric bypass","volume":"29","author":"Xu","year":"2019","journal-title":"Obes Surg"},{"issue":"9","key":"10.1016\/j.obpill.2022.100018_bib138","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1038\/s41366-020-0541-7","article-title":"Secretin release after Roux-en-Y gastric bypass reveals a population of glucose-sensitive S cells in distal small intestine","volume":"44","author":"Modvig","year":"2020","journal-title":"Int J Obes (Lond)"},{"key":"10.1016\/j.obpill.2022.100018_bib139","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s12272-019-01138-9","article-title":"Hypothalamic inflammation and obesity: a mechanistic review","volume":"42","author":"Seong","year":"2019","journal-title":"Arch Pharm Res (Seoul)"},{"key":"10.1016\/j.obpill.2022.100018_bib140","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s13679-018-0300-4","article-title":"Future pharmacotherapy for obesity: new anti-obesity drugs on the horizon","volume":"7","author":"Srivastava","year":"2018","journal-title":"Curr Obes Rep"},{"key":"10.1016\/j.obpill.2022.100018_bib141","doi-asserted-by":"crossref","first-page":"4B","DOI":"10.1016\/j.amjcard.2012.08.029","article-title":"Adiposopathy, diabetes mellitus, and primary prevention of atherosclerotic coronary artery disease: treating \"sick fat\u201d through improving fat function with antidiabetes therapies","volume":"110","author":"Bays","year":"2012","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.obpill.2022.100018_bib142","article-title":"Glucagon like peptide-1 promotes adipocyte differentiation via the Wnt4 mediated sequestering of beta-catenin","volume":"11","author":"Liu","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.obpill.2022.100018_bib143","doi-asserted-by":"crossref","DOI":"10.1590\/1414-431x20165826","article-title":"Glucagon-like peptide 1 improves insulin resistance in vitro through anti-inflammation of macrophages","volume":"49","author":"Guo","year":"2016","journal-title":"Braz J Med Biol Res"},{"key":"10.1016\/j.obpill.2022.100018_bib144","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.peptides.2017.11.013","article-title":"Problem or solution: the strange story of glucagon","volume":"100","author":"Scott","year":"2018","journal-title":"Peptides"},{"key":"10.1016\/j.obpill.2022.100018_bib145","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1007\/s00125-017-4354-8","article-title":"GLP-1\/glucagon receptor co-agonism for treatment of obesity","volume":"60","author":"Sanchez-Garrido","year":"2017","journal-title":"Diabetologia"},{"key":"10.1016\/j.obpill.2022.100018_bib146","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/bph.15638","article-title":"Brain GLP-1 and the regulation of food intake: GLP-1 action in the brain and its implications for GLP-1 receptor agonists in obesity treatment","volume":"179","author":"Trapp","year":"2022","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.obpill.2022.100018_bib147","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.tem.2020.02.006","article-title":"How may GIP enhance the therapeutic efficacy of GLP-1?","volume":"31","author":"Samms","year":"2020","journal-title":"Trends Endocrinol Metabol: TEM (Trends Endocrinol Metab)"},{"key":"10.1016\/j.obpill.2022.100018_bib148","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2019.170196","article-title":"Metabolism of GIP and the contribution of GIP to the glucose-lowering properties of DPP-4 inhibitors","volume":"125","author":"Deacon","year":"2020","journal-title":"Peptides"},{"key":"10.1016\/j.obpill.2022.100018_bib149","doi-asserted-by":"crossref","first-page":"e2710","DOI":"10.1210\/clinem\/dgaa327","article-title":"GIP as a therapeutic target in diabetes and obesity: insight from incretin Co-agonists","volume":"105","author":"Holst","year":"2020","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"key":"10.1016\/j.obpill.2022.100018_bib150","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2019.170201","article-title":"Effects on pancreatic Beta and other Islet cells of the glucose-dependent insulinotropic polypeptide","volume":"125","author":"Khan","year":"2020","journal-title":"Peptides"},{"key":"10.1016\/j.obpill.2022.100018_bib151","doi-asserted-by":"crossref","first-page":"3103","DOI":"10.2337\/db11-0979","article-title":"Glucose-dependent insulinotropic polypeptide: a bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans","volume":"60","author":"Christensen","year":"2011","journal-title":"Diabetes"},{"key":"10.1016\/j.obpill.2022.100018_bib152","doi-asserted-by":"crossref","DOI":"10.3390\/life12010029","article-title":"Role of a dual glucose-dependent insulinotropic peptide (GIP)\/Glucagon-like peptide-1 receptor agonist (twincretin) in glycemic control: from pathophysiology to treatment","volume":"12","author":"Pelle","year":"2021","journal-title":"Life"},{"key":"10.1016\/j.obpill.2022.100018_bib153","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.2337\/dbi21-0004","article-title":"The role of GIP in the regulation of GLP-1 satiety and nausea","volume":"70","author":"Hayes","year":"2021","journal-title":"Diabetes"},{"key":"10.1016\/j.obpill.2022.100018_bib154","article-title":"Glucose-dependent insulinotropic polypeptide modifies adipose plasticity and promotes beige adipogenesis of human omental adipose-derived stem cells","volume":"35","author":"Chen","year":"2021","journal-title":"Faseb J"},{"key":"10.1016\/j.obpill.2022.100018_bib155","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1128\/MCB.00256-14","article-title":"A\u00a0naturally occurring GIP receptor variant undergoes enhanced agonist-induced desensitization, which impairs GIP control of adipose insulin sensitivity","volume":"34","author":"Mohammad","year":"2014","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.obpill.2022.100018_bib156","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.metabol.2019.04.014","article-title":"The incretin system in healthy humans: the role of GIP and GLP-1","volume":"96","author":"Holst","year":"2019","journal-title":"Metab, Clin Exp"},{"key":"10.1016\/j.obpill.2022.100018_bib157","article-title":"What combines best with GLP-1 for obesity treatment: GIP receptor agonists or antagonists?","volume":"2","author":"Holst","year":"2021","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.obpill.2022.100018_bib158","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.biopha.2018.08.088","article-title":"Recent updates on GLP-1 agonists: current advancements & challenges","volume":"108","author":"Sharma","year":"2018","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.obpill.2022.100018_bib159","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1007\/s13300-021-01113-y","article-title":"Contemporary classification of glucagon-like peptide 1 receptor agonists (GLP1RAs)","volume":"12","author":"Kalra","year":"2021","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.obpill.2022.100018_bib160","doi-asserted-by":"crossref","first-page":"29959","DOI":"10.1073\/pnas.2014879117","article-title":"Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist","volume":"117","author":"Kawai","year":"2020","journal-title":"Proc Natl Acad Sci Unit States Am"},{"key":"10.1016\/j.obpill.2022.100018_bib161","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3803\/EnM.2021.102","article-title":"Peptidyl and non-peptidyl oral glucagon-like peptide-1 receptor agonists","volume":"36","author":"Choe","year":"2021","journal-title":"Endocrinol Metab (Seoul)"},{"key":"10.1016\/j.obpill.2022.100018_bib162","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s13300-020-00981-0","article-title":"The role of tirzepatide, dual GIP and GLP-1 receptor agonist, in the management of type 2 diabetes: the SURPASS clinical trials","volume":"12","author":"Min","year":"2021","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.obpill.2022.100018_bib163","doi-asserted-by":"crossref","first-page":"196","DOI":"10.7570\/jomes21033","article-title":"Next generation antiobesity medications: setmelanotide, semaglutide, tirzepatide and bimagrumab: what do they mean for clinical practice?","volume":"30","author":"Ryan","year":"2021","journal-title":"J\u00a0Obes Metab Syndr"},{"key":"10.1016\/j.obpill.2022.100018_bib164","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1080\/14728214.2021.1947240","article-title":"Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity","volume":"26","author":"Jepsen","year":"2021","journal-title":"Expet Opin Emerg Drugs"},{"key":"10.1016\/j.obpill.2022.100018_bib165","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1089\/met.2018.0075","article-title":"Combination therapies for obesity","volume":"16","author":"Camilleri","year":"2018","journal-title":"Metab Syndr Relat Disord"},{"key":"10.1016\/j.obpill.2022.100018_bib166","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.120188","article-title":"The current significance and prospects for the use of dual receptor agonism GLP-1\/Glucagon","volume":"288","author":"Spezani","year":"2022","journal-title":"Life Sci"},{"key":"10.1016\/j.obpill.2022.100018_bib167","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/nm.3761","article-title":"A\u00a0rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents","volume":"21","author":"Finan","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.obpill.2022.100018_bib168","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1210\/jc.2006-1806","article-title":"Efficacy and safety of intranasal peptide YY3-36 for weight reduction in obese adults","volume":"92","author":"Gantz","year":"2007","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"key":"10.1016\/j.obpill.2022.100018_bib169","doi-asserted-by":"crossref","first-page":"11183","DOI":"10.1021\/acs.jmedchem.1c00565","article-title":"Development of cagrilintide, a long-acting amylin analogue","volume":"64","author":"Kruse","year":"2021","journal-title":"J\u00a0Med Chem"},{"issue":"3","key":"10.1016\/j.obpill.2022.100018_bib170","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41573-021-00337-8","article-title":"Anti-obesity drug discovery: advances and challenges","volume":"21","author":"Muller","year":"2022","journal-title":"Nat Rev Drug Discov."},{"key":"10.1016\/j.obpill.2022.100018_bib171","doi-asserted-by":"crossref","DOI":"10.1098\/rsob.210080","article-title":"Ghrelin octanoylation by ghrelin O-acyltransferase: protein acylation impacting metabolic and neuroendocrine signalling","volume":"11","author":"Davis","year":"2021","journal-title":"Open Biology"},{"key":"10.1016\/j.obpill.2022.100018_bib172","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.canlet.2020.11.026","article-title":"FGF21 in obesity and cancer: new insights","volume":"499","author":"Lu","year":"2021","journal-title":"Cancer Lett"},{"key":"10.1016\/j.obpill.2022.100018_bib173","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/s41574-020-0386-0","article-title":"The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic","volume":"16","author":"Geng","year":"2020","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.obpill.2022.100018_bib174","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1111\/dom.13023","article-title":"Once-weekly administration of a long-acting fibroblast growth factor 21 analogue modulates lipids, bone turnover markers, blood pressure and body weight differently in obese people with hypertriglyceridaemia and in non-human primates","volume":"19","author":"Kim","year":"2017","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.obpill.2022.100018_bib175","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan8732","article-title":"Long-acting MIC-1\/GDF15 molecules to treat obesity: evidence from mice to monkeys","volume":"9","author":"Xiong","year":"2017","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.obpill.2022.100018_bib176","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1080\/14656566.2019.1692815","article-title":"Anorectic state of obesity medications in the United States. Are leaner times ahead?","volume":"21","author":"Li","year":"2020","journal-title":"Expet Opin Pharmacother"},{"key":"10.1016\/j.obpill.2022.100018_bib177","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1074\/jbc.REV119.007363","article-title":"Opportunities and challenges in the therapeutic activation of human energy expenditure and thermogenesis to manage obesity","volume":"295","author":"Chen","year":"2020","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.obpill.2022.100018_bib178","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3389\/fphys.2015.00036","article-title":"Mitochondrial uncoupling proteins and energy metabolism","volume":"6","author":"Busiello","year":"2015","journal-title":"Front Physiol"},{"key":"10.1016\/j.obpill.2022.100018_bib179","doi-asserted-by":"crossref","DOI":"10.3390\/cells8080795","article-title":"Mitochondrial uncoupling: a key controller of biological processes in physiology and diseases","volume":"8","author":"Demine","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.obpill.2022.100018_bib180","doi-asserted-by":"crossref","first-page":"6214","DOI":"10.1039\/D1FO00780G","article-title":"Roles of amino acid derivatives in the regulation of obesity","volume":"12","author":"Zheng","year":"2021","journal-title":"Food Funct"},{"key":"10.1016\/j.obpill.2022.100018_bib181","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/jcp.25450","article-title":"Browning of white fat: novel insight into factors, mechanisms, and therapeutics","volume":"232","author":"Jeremic","year":"2017","journal-title":"J\u00a0Cell Physiol"},{"key":"10.1016\/j.obpill.2022.100018_bib182","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2020.154246","article-title":"11\u03b2-hydroxysteroid dehydrogenase type 1 inhibitor use in human disease-a systematic review and narrative synthesis","volume":"108","author":"Gregory","year":"2020","journal-title":"Metab, Clin Exp"},{"key":"10.1016\/j.obpill.2022.100018_bib183","doi-asserted-by":"crossref","first-page":"559","DOI":"10.2337\/dbi19-0009","article-title":"Energy regulation mechanism and therapeutic potential of asprosin","volume":"69","author":"Hoffmann","year":"2020","journal-title":"Diabetes"},{"key":"10.1016\/j.obpill.2022.100018_bib184","doi-asserted-by":"crossref","first-page":"743","DOI":"10.2147\/DMSO.S182953","article-title":"Early effects of roflumilast on insulin sensitivity in adults with prediabetes and overweight\/obesity involve age-associated fat mass loss - results of an exploratory study","volume":"12","author":"Muo","year":"2019","journal-title":"Diabetes Metab Syndr Obes"},{"key":"10.1016\/j.obpill.2022.100018_bib185","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.33457","article-title":"Effect of Bimagrumab vs placebo on body fat mass among adults with type 2 diabetes and obesity: a phase 2 randomized clinical trial","volume":"4","author":"Heymsfield","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.obpill.2022.100018_bib186","doi-asserted-by":"crossref","DOI":"10.1126\/science.abf8683","article-title":"Sequencing of 640,000 exomes identifies GPR75 variants associated with protection from obesity","volume":"373","author":"Akbari","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.obpill.2022.100018_bib187","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.biochi.2022.01.005","article-title":"GPR75: an exciting new target in metabolic syndrome and related disorders","volume":"195","author":"Murtaza","year":"2022","journal-title":"Biochimie"},{"key":"10.1016\/j.obpill.2022.100018_bib188","doi-asserted-by":"crossref","first-page":"37","DOI":"10.7774\/cevr.2014.3.1.37","article-title":"Prophylactic and therapeutic vaccines for obesity","volume":"3","author":"Na","year":"2014","journal-title":"Clin Exp Vaccine Res"},{"key":"10.1016\/j.obpill.2022.100018_bib189","doi-asserted-by":"crossref","first-page":"887","DOI":"10.4161\/hv.27537","article-title":"Obesity vaccines","volume":"10","author":"Monteiro","year":"2014","journal-title":"Hum Vaccines Immunother"},{"key":"10.1016\/j.obpill.2022.100018_bib190","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/osp4.343","article-title":"Safety, tolerability and efficacy of a novel self-use biodegradable device for management of obesity","volume":"5","author":"Shirin","year":"2019","journal-title":"Obes Sci Pract"},{"issue":"Suppl 1","key":"10.1016\/j.obpill.2022.100018_bib191","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/dom.13129","article-title":"Incretin hormones: their role in health and disease","volume":"20","author":"Nauck","year":"2018","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.obpill.2022.100018_bib192","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(21)01324-6","article-title":"Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial","volume":"398","author":"Rosenstock","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.obpill.2022.100018_bib193","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Fr\u00edas","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.obpill.2022.100018_bib194","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0140-6736(21)01443-4","article-title":"Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial","volume":"398","author":"Ludvik","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.obpill.2022.100018_bib195","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1016\/S0140-6736(21)02188-7","article-title":"Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial","volume":"398","author":"Del Prato","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.obpill.2022.100018_bib196","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1001\/jama.2022.0078","article-title":"Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial","volume":"327","author":"Dahl","year":"2022","journal-title":"JAMA : J Am Med Assoc"},{"key":"10.1016\/j.obpill.2022.100018_bib197","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.obpill.2022.100018_bib198","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.obpill.2022.100018_bib200","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.obpill.2022.100018_bib201","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1001\/archsurg.1976.01360210023004","article-title":"Why control blood glucose levels?","volume":"111","author":"Rossini","year":"1976","journal-title":"Arch Surg"},{"key":"10.1016\/j.obpill.2022.100018_bib202","first-page":"20","article-title":"New controversies in hypertension: questions answered, answers questioned","volume":"18","author":"Ryan","year":"1992","journal-title":"Compr Ther"},{"key":"10.1016\/j.obpill.2022.100018_bib203","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1097\/00007611-199004000-00019","article-title":"Cholesterol: myth or reality?","volume":"83","author":"Thompson","year":"1990","journal-title":"South Med J"},{"key":"10.1016\/j.obpill.2022.100018_bib204","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1136\/bmj.304.6828.713","article-title":"The cholesterol controversy","volume":"304","author":"Tobert","year":"1992","journal-title":"BMJ"},{"key":"10.1016\/j.obpill.2022.100018_bib205","first-page":"98","article-title":"The oral antidiabetic agents","volume":"13","author":"Bierman","year":"1976","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.obpill.2022.100018_bib206","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/s00592-014-0698-4","article-title":"Systematic review and meta-analysis of randomized clinical trials comparing efficacy and safety outcomes of insulin glargine with NPH insulin, premixed insulin preparations or with insulin detemir in type 2 diabetes mellitus","volume":"52","author":"Rys","year":"2015","journal-title":"Acta Diabetol"},{"key":"10.1016\/j.obpill.2022.100018_bib207","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/dmrr.411","article-title":"All-cause mortality in diabetic patients treated with combinations of sulfonylureas and biguanides","volume":"20","author":"Mannucci","year":"2004","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.obpill.2022.100018_bib208","first-page":"430","article-title":"Antihypertensive pharmacology","volume":"132","author":"Gerber","year":"1980","journal-title":"West J Med"},{"key":"10.1016\/j.obpill.2022.100018_bib209","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1097\/MOL.0b013e3283325083","article-title":"What's the deal with niacin development: is laropiprant add-on therapy a winning strategy to beat a straight flush?","volume":"20","author":"Bays","year":"2009","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.obpill.2022.100018_bib210","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.jacl.2012.04.003","article-title":"Treatment options for the management of hypertriglyceridemia: strategies based on the best-available evidence","volume":"6","author":"Maki","year":"2012","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.obpill.2022.100018_bib211","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1097\/MJT.0b013e31815a69fc","article-title":"The 'forgotten' bile acid sequestrants: is now a good time to remember?","volume":"14","author":"Bays","year":"2007","journal-title":"Am J Therapeut"},{"key":"10.1016\/j.obpill.2022.100018_bib212","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1021\/acschembio.5b00787","article-title":"Design of potent and proteolytically stable oxyntomodulin analogs","volume":"11","author":"Muppidi","year":"2016","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.obpill.2022.100018_bib213","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.jacl.2013.04.001","article-title":"Obesity, adiposity, and dyslipidemia: a consensus statement from the National Lipid Association","volume":"7","author":"Bays","year":"2013","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.obpill.2022.100018_bib214","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.1016\/j.jacc.2013.11.004","article-title":"2013 AHA\/ACC\/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology\/American Heart Association task force on practice guidelines and the obesity Society","volume":"63","author":"Jensen","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.obpill.2022.100018_bib215","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s11883-014-0409-1","article-title":"Adiposopathy, \"sick fat,\u201d Ockham's razor, and resolution of the obesity paradox","volume":"16","author":"Bays","year":"2014","journal-title":"Curr Atherosclerosis Rep"},{"key":"10.1016\/j.obpill.2022.100018_bib216","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2021.100149","article-title":"Ten things to know about ten cardiovascular disease risk factors","volume":"5","author":"Bays","year":"2021","journal-title":"Am J Prev Cardiol"},{"key":"10.1016\/j.obpill.2022.100018_bib217","doi-asserted-by":"crossref","first-page":"536","DOI":"10.4158\/EP13176.CS","article-title":"American Association of Clinical Endocrinologists' comprehensive diabetes management algorithm 2013 consensus statement--executive summary","volume":"19","author":"Garber","year":"2013","journal-title":"Endocr Pract"},{"key":"10.1016\/j.obpill.2022.100018_bib218","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1001\/jama.2013.284427","article-title":"2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8)","volume":"311","author":"James","year":"2014","journal-title":"JAMA : J Am Med Assoc"},{"key":"10.1016\/j.obpill.2022.100018_bib219","doi-asserted-by":"crossref","first-page":"S81","DOI":"10.2337\/dc19-S008","article-title":"8. Obesity management for the treatment of type 2 diabetes: standards of medical care in diabetes-2019","volume":"42","author":"American Diabetes","year":"2019","journal-title":"Diabetes Care"},{"issue":"25","key":"10.1016\/j.obpill.2022.100018_bib220","first-page":"e1082","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.obpill.2022.100018_bib221","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/oby.20181","article-title":"Obesity-related hypertension: pathogenesis, cardiovascular risk, and treatment--a position paper of the the Obesity Society and the American Society of Hypertension","volume":"21","author":"Landsberg","year":"2013","journal-title":"Obesity"},{"key":"10.1016\/j.obpill.2022.100018_bib222","series-title":"Clinical practice guidelines we can trust","author":"Graham","year":"2011"}],"updated-by":[{"DOI":"10.1016\/j.obpill.2022.100035","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000}}],"container-title":["Obesity Pillars"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667368122000092?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667368122000092?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,11]],"date-time":"2024-05-11T21:34:53Z","timestamp":1715463293000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667368122000092"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":209,"alternative-id":["S2667368122000092"],"URL":"https:\/\/doi.org\/10.1016\/j.obpill.2022.100018","relation":{},"ISSN":["2667-3681"],"issn-type":[{"value":"2667-3681","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022","name":"articletitle","label":"Article Title"},{"value":"Obesity Pillars","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.obpill.2022.100018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc. on behalf of Obesity Medicine Association.","name":"copyright","label":"Copyright"}],"article-number":"100018"}}